Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
Definition
Biotechnology research firms fail to submit required clinical trial registration, results, or certifications to ClinicalTrials.gov, or submit false/misleading data, triggering FDA enforcement. The FDA issues a Notice of Noncompliance with 30 days to remedy; uncorrected violations lead to escalating daily penalties. This is systemic for biotech sponsors of applicable clinical trials involving drugs, biologics, or devices, especially high-risk trials for serious diseases.
Key Findings
- Financial Impact: $10,000 per day per violation
- Frequency: Daily (ongoing until corrected)
- Root Cause: Failure to comply with FDAAA requirements under 42 U.S.C. 282(j), often due to inadequate bioresearch monitoring, poor data management in biosafety/compliance workflows, or patterns of prior noncompliance detected via FDA inspections/complaints.
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Clinical Trial Sponsors, Regulatory Affairs Managers, Compliance Officers, Bioresearch Monitors
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
- https://www.loeb.com/en/insights/publications/2020/08/final-fda-guidance-on-civil-money-penalties-relating-to-the-clinicaltrialsgov-data-bank
- https://www.fda.gov/regulatory-information/search-fda-guidance-documents/civil-money-penalties-relating-clinicaltrialsgov-data-bank
- https://www.healthlawupdate.com/blogs/are-you-complying-with-clinicaltrials-gov-reporting-obligations/